Veritas In Silico (TSE:130A) Marketable Securities: 円0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
29 GF Score
Price 円448.00
GF Value 円268.87
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico Marketable Securities?

Veritas In Silico TSE:130A +0.67% 29 Marketable Securities is 円0.00 Mil as of Jun. 2026. GuruFocus rates TSE:130A with a GF Score™ of 29/100 and a GF Value™ of 円268.87 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Veritas In Silico's Marketable Securities for the quarter that ended in Jun. 2026 was 円0.00 Mil.

Veritas In Silico  (TSE:130A) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Veritas In Silico Marketable Securities Related Terms

Veritas In Silico Marketable Securities Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico Marketable Securities Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00 0.00 0.00

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:130A
29GF Score
Veritas In Silico Inc TSE:130A
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円0.00 Mil mean?
Veritas In Silico (TSE:130A) has a Marketable Securities of 円0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Veritas In Silico and its competitors.
Is Veritas In Silico's Marketable Securities too high?
Veritas In Silico's current Marketable Securities is 円0.00 Mil. Overall, Veritas In Silico has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Marketable Securities compare to VRTX and REGN?
Veritas In Silico's Marketable Securities of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Veritas In Silico and its competitors. Veritas In Silico's current Marketable Securities is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円268.87, compared to a current price of 円448.00 — trading 66.6% above its estimated fair value. The current Marketable Securities is 円0.00 Mil. Veritas In Silico's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Marketable Securities is 円0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veritas In Silico (TSE:130A) Overvalued in 2026?

Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued. The current stock price of 円448.00 is trading 66.6% above its estimated GF Value™ of 円268.87. GuruFocus considers Veritas In Silico to be Significantly Overvalued.

Key valuation signals for TSE:130A:

  • Marketable Securities: 円0.00 Mil
  • GF Value™: 円268.87 vs. price of 円448.00 (66.6% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
29GF Score

Get the complete analysis for TSE:130A

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円448.00
Price
円268.87
GF Value